X4 Pharmaceuticals, Inc. develops and commercializes therapies for rare diseases of the immune system. The company has received U.S. approval for its product XOLREMDI® (mavorixafor) and is advancing this therapy for additional patient populations, including those with chronic neutropenic disorders through a global Phase 3 clinical trial. X4 is headquartered in Boston, Massachusetts.
- Website
- www.x4pharma.com
- Issuer profile
- All listings